Home Newsfeeds Spirit Sets Oct. 19 Shareholder Vote On Acquisition By Jetblue – SEC

Spirit Sets Oct. 19 Shareholder Vote On Acquisition By Jetblue – SEC

https://www.sec.gov/Archives/edgar/data/1498710/000119312522242974/d378607ddefm14a.htm

byBenzinga Newsdesk

September 12, 2022

1 minute read

https://www.sec.gov/Archives/edgar/data/1498710/000119312522242974/d378607ddefm14a.htm

T-Mobile US’ Pricing Power Of 5G Is A Pivot Point, Analyst Says

By Anusuya Lahiri

October 18, 2:45 PM

Benchmark analyst Matthew Harrigan reiterated a Buy on T-Mobile US, Inc (NASDAQ:TMUS) and cut the price target to $197 from $205. The…

AAPL

Using Pepsi’s Premarket Price Action To Trade Q2 Earnings

By Joel Elconin

July 12, 2:31 PM

Even if you do not participate in after-hours and premarket trading, there is excellent information that can be derived from those sessions.

PEP

Mill City Ventures III Q4 Sales $847.52K Up From $678.21K YoY; Investment Income From Lending Operations Increases 58%; Shareholder Equity Increases 36.7%

By Happy Mohamed

April 17, 11:59 AM

Mill City Ventures III (NASDAQ:MCVT) reported $847.52 thousand in sales this quarter. This is a 24.96 percent increase over sales of $678.21 thousand the same period last year. 2022 Highlights Investment income from

MCVT

Gene Therapy Player REGENXBIO’s RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst

By Vandana Singh

February 12, 3:35 PM

Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.

DNLI

Spirit Sets Oct. 19 Shareholder Vote On Acquisition By Jetblue – SEC

Related Posts

T-Mobile US’ Pricing Power Of 5G Is A Pivot Point, Analyst Says

Using Pepsi’s Premarket Price Action To Trade Q2 Earnings

Mill City Ventures III Q4 Sales $847.52K Up From $678.21K YoY; Investment Income From Lending Operations Increases 58%; Shareholder Equity Increases 36.7%

Gene Therapy Player REGENXBIO’s RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst